Author:
Yu Evan Y.,Ferrario Cristiano,Linch Mark D.,Stoeckle Michael,Laguerre Brigitte,Arranz Jose A.,Todenhöfer Tilman,Fong Peter C.,Piulats Josep M.,Berry William,Emmenegger Urban,Mourey Loic,Joshua Anthony M.,Mar Nataliya,Appleman Leonard J.,Conter Henry J.,Gravis Gwenaelle,Li Xin Tong,Schloss Charles,Poehlein Christian,de Bono Johann S.
Reference27 articles.
1. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer;Rice;Front Oncol,2019
2. Safety and efficacy of first-line treatments for chemotherapy-naive metastatic castration-resistant prostate cancer: a systematic review and indirect comparison;Zheng;BioMed Res Int,2017
3. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Parker;Ann Oncol,2020
4. Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer 2022. Arnhem, Netherlands: European Association of Urology; 2022.
5. Janssen. ZYTIGA® (abiraterone acetate) tablets, for oral use. 08/2021. Horsham, PA: Janssen Biotech, Inc.; 2021.